Ruilong Pharmaceutical

Ruilong Pharmaceutical is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to the discovery and development of innovative therapies for autoimmune diseases and oncology. The company focuses on high-potential targets such as JAK1 and TYK2 to address significant unmet medical needs in dermatology and rheumatology. Its lead programs are currently undergoing Phase 2 clinical trials, demonstrating a commitment to advancing next-generation small molecules and biologics. Ruilong Pharmaceutical leverages its internal R&D capabilities to build a robust pipeline aimed at providing more effective and safer treatment options for patients globally.